FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
Enrollment continues in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 studies of MDMA-assisted therapy for the treatment of PTSD. You are eligible to participate …
As of September 13, 100 participants have participated in MPLONG, a long-term follow-up observational study for participants in MAPS-sponsored Phase 3 MDMA-assisted therapy studies for the treatment of …
Enrollment is continuing for our long-term follow up study for our MDMA-assisted therapy parent studies. The long-term follow up study is open to individuals who participated and received MDMA in at least …
MAPS PBC has begun collecting long-term follow-up data from previous study participants to determine the long-term safety and persistence of effectiveness of MDMA-assisted therapy at least 6 months after …
